These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12113097)

  • 1. Novuspharma announces preliminary results of phase II trials for BBR 3464.
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):325-6. PubMed ID: 12113097
    [No Abstract]   [Full Text] [Related]  

  • 2. Platinum-based chemotherapy for inoperable non-small cell lung cancer: a real therapeutic progress?
    Buccheri G
    Lung Cancer; 1994 Jul; 11(1-2):115-7. PubMed ID: 7521731
    [No Abstract]   [Full Text] [Related]  

  • 3. New platinum derivatives in advanced non-small cell lung cancer.
    Crinò L; Cappuzzo F
    Suppl Tumori; 2002; 1(4):S24-5. PubMed ID: 12415810
    [No Abstract]   [Full Text] [Related]  

  • 4. TNO6 in non small cell lung cancer.
    Osborne RJ; Slevin ML; Wrigley PF; Franks CR
    Eur J Cancer Clin Oncol; 1987 Jan; 23(1):109-10. PubMed ID: 3036535
    [No Abstract]   [Full Text] [Related]  

  • 5. Carboplatin: current status and future prospects.
    Canetta R; Bragman K; Smaldone L; Rozencweig M
    Cancer Treat Rev; 1988 Jun; 15 Suppl B():17-32. PubMed ID: 2841021
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cisplatinum compounds].
    Ota K
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):50-8. PubMed ID: 8380687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fine points of end points: phase II trials in lung cancer.
    Gelmon KA
    Ann Oncol; 1998 Oct; 9(10):1045-6. PubMed ID: 9834815
    [No Abstract]   [Full Text] [Related]  

  • 8. [Studies of the clinical use of cycloplatin--a new derivative of cisplatin].
    Koralewski P; Pawlicki M
    Przegl Lek; 1992; 49(4):120-2. PubMed ID: 1332130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
    Zhang P; Feng FY; Wu LY; Hu Y; Liu JW; Gao YJ; Guan XQ; Nan KJ; Suo AL; Wang XW; Zhang MH; Zhang WD; Li CW; Zhang Y; Zhao JB
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):230-4. PubMed ID: 16875614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab Outperforms Docetaxel for NSCLC.
    Leslie M
    Cancer Discov; 2016 Mar; 6(3):223. PubMed ID: 26811324
    [No Abstract]   [Full Text] [Related]  

  • 11. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
    Raez LE; Kobina S; Santos ES
    Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oxaliplatin].
    Bascioni R
    Suppl Tumori; 2004; 3(4):S111-2. PubMed ID: 15206232
    [No Abstract]   [Full Text] [Related]  

  • 13. [A phase I study of carboplatin].
    Ogawa M; Imajo K; Horikoshi N; Inoue K; Mukaiyama T; Yamazaki H; Ueno K; Nakamura T; Aiba K; Kuraishi Y
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1292-6. PubMed ID: 3034170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
    Stewart DJ
    J Natl Cancer Inst; 2008 Mar; 100(6):445-6; author reply 446. PubMed ID: 18334712
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II oncology trials: let's be positive.
    Ratain MJ
    Clin Cancer Res; 2005 Aug; 11(16):5661-2. PubMed ID: 16115898
    [No Abstract]   [Full Text] [Related]  

  • 16. [Nedaplatin].
    Ota K
    Gan To Kagaku Ryoho; 1996 Feb; 23(3):379-87. PubMed ID: 8712835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State of the art in systemic treatment of lung cancer.
    Giaccone G
    Eur J Cancer; 2001 Oct; 37 Suppl 7():S99-114. PubMed ID: 11888010
    [No Abstract]   [Full Text] [Related]  

  • 18. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
    Abou-Jawde RM; Oberoi SS
    J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
    [No Abstract]   [Full Text] [Related]  

  • 19. Ovarian trials at the Royal Marsden.
    Wiltshaw E
    Cancer Treat Rev; 1985 Sep; 12 Suppl A():67-71. PubMed ID: 3910224
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
    DeGrendele H
    Clin Lung Cancer; 2003 Sep; 5(2):83-5. PubMed ID: 14596689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.